The world's leading legal directory Chambers and Partners recently published its Life Sciences Global Practice Guide (2023) (the "Guide"). Han Kun again contributed the China chapter of the Guide's Trends and Developments section. The contributors include Min Zhu, Yaling (Michelle) Gon, Yang (Aaron) Gu, Lu Chai, Dr. Ying Li, and Shiye Yuan.
The Guide features 23 jurisdictions and provides the latest information on challenging the decisions of regulatory bodies; clinical trials; the marketing, manufacturing, and distribution of pharmaceuticals and medical devices; pricing; digital healthcare; patents; and developments related to COVID-19. The Guide's China chapter covers major changes in venture capital/private equity financing, merger and acquisition, and license-in/out deals in the life sciences industry; drug and medical device regulatory developments; compliance practices in respect of commercial bribery, data compliance, and ESG (environmental, social and governance); and new Chinese intellectual property regulations and tax incentives for the life sciences industry.
Han Kun has a dedicated life sciences and healthcare team and has been consistently ranked as a leading law firm in the life sciences and healthcare sector by authoritative legal directories, including Chambers and Partners, The Legal 500, Asialaw Profiles, and China Business Law Journal. The firm is committed to providing clients in the life sciences and healthcare sector with comprehensive legal services, including private equity and venture capital, mergers and acquisitions, onshore and offshore capital markets, pharmaceutical license in/out, and asset sale/purchase transactions, intellectual property, compliance and regulatory, data protection, and dispute resolution.
